SAN DIEGO, Sep 21, 2011 (BUSINESS WIRE) —
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will present at the Sixth Annual JMP SecuritiesHealthcare Conference on Wednesday, September 28, 2011, at 12:00 p.m.Eastern Time at The St. Regis Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through October 12, 2011.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA has a portfolio of four productcandidates including pimavanserin, which is in Phase III development asa potential first-in-class treatment for Parkinson's disease psychosis.ACADIA also has a product candidate in Phase II for chronic pain and aproduct candidate in Phase I for glaucoma, both in collaboration withAllergan, Inc. as well as a product candidate in IND-track developmentfor schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. Allof the product candidates in ACADIA's pipeline emanate from discoveriesmade using its proprietary drug discovery platform. ACADIA maintains awebsite at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA'sdrug discovery and development programs either alone or with a partner,including clinical trials, and the benefits to be derived from ACADIA'sproduct candidates, in each case including pimavanserin. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA's annual report on Form 10-K for the year ended December 31, 2010as well as other subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.
SOURCE: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
858-558-2871